TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference
November 03 2023 - 7:30AM
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael
S. Weiss, the Company’s Chairman and Chief Executive Officer, will
participate in the 5th Annual Guggenheim Inflammation, Neurology
& Immunology (INI) Conference, being held at the JW Marriott
Essex House, in New York City on November 6 -7, 2023. The fireside
chat is scheduled to take place on Monday, November 6, 2023, at
3:10 PM ET.
A live webcast of the fireside chat will be available on the
Events page, located within the Investors & Media section, of
the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICSTG Therapeutics is a fully
integrated, commercial stage, biopharmaceutical company focused on
the acquisition, development and commercialization of novel
treatments for B-cell diseases. In addition to a research pipeline
including several investigational medicines, TG has received
approval from the U.S. FDA for BRIUMVI® (ublituximab-xiiy), for the
treatment of adult patients with relapsing forms of multiple
sclerosis, to include clinically isolated syndrome,
relapsing-remitting disease, and active secondary progressive
disease, as well as European Commission (EC) approval for BRIUMVI
to treat adult patients with RMS who have active disease defined by
clinical or imaging features. For more information, visit
www.tgtherapeutics.com, and follow us on
Twitter @TGTherapeutics and on LinkedIn.
CONTACT:
Investor RelationsEmail:
ir@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:Email:
media@tgtxinc.com Telephone: 1.877.575.TGTX (8489), Option
6
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TG Therapeutics (NASDAQ:TGTX)
Historical Stock Chart
From Apr 2023 to Apr 2024